Kanyr Pharma

Kanyr Pharma was founded in May 2013. It holds the rights to two major cancer programs: PRL-PTP inhibitors and ImmunyrTM technology. Kanyr's research team has over 15 years of experience in the PTP field and is a world leader in understanding how to chemically target the PTP gene family. The PTP gene family is associated with various human diseases but remains one of the few underexplored areas in drug development.